Perspectives on cellular dysfunction in nonalcoholic steatohepatitis: A case of 'multiorganelle failure'? Proceedings of a virtual workshop on nonalcoholic steatohepatitis

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 2, 2011, Pages 135-139

  Lonardo, Amedeo ^a,b   Loria, Paola ^a   Argo, Curtis ^c   Caldwell, Stephen ^c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Nuovo Ospedale S Agostino   (Italy)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

cell biology; history of medicine; NAFLD; NASH; pathogenesis; synonyms

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN B; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; AUTOPHAGY; CELL DAMAGE; CYTOSKELETON; DISEASE PREDISPOSITION; ENERGY YIELD; FIBROGENESIS; GENETIC ASSOCIATION; HEPATITIS C; HUMAN; INFLAMMATION; INSULIN RESISTANCE; IRON OVERLOAD; LIVER FIBROSIS; METABOLIC SYNDROME X; MORTALITY; MULTIORGANELLE FAILURE; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; REVIEW; RISK FACTOR; SCORING SYSTEM;

ENERGY METABOLISM; FATTY LIVER; FEMALE; FIBROSIS; HUMANS; INFLAMMATION; LIPID METABOLISM; ORGANELLES;

EID: 79954517674     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.11.24     Document Type: Review

References (60)

1. Zelman S. The liver in obesity. AMA Arch. Intern. Med. 90, 141-156 (1952).
2. Thaler H. [The fatty liver and its pathogenetic relation to liver cirrhosis]. Virchows Arch. Pathol. Anat. Physiol. Klin. Med. 335, 180-210 (1962).
3. Itoh S, Tsukada Y, Motomura Y, Ichinoe A. Five patients with nonalcoholic diabetic cirrhosis. Acta Hepatogastroenterol. (Stuttg.) 26, 90-97 (1979). (Pubitemid 9168824)
4. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55, 434-438 (1980). (Pubitemid 10057164)
5. Batman PA, Scheuer PJ. Diabetic hepatitis preceding the onset of glucose intolerance. Histopathology 9, 237-243 (1985). (Pubitemid 15136727)
6. Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury Gastroenterology 95, 1056-1062 (1988).
7. Lonardo A, Bellini M, Tondelli E et al. Nonalcoholic steatohepatitis and the 'bright liver syndrome': should a recently expanded clinical entity be further expanded? Am. J. Gastroenterol. 90, 2072-2074 (1995).
8. Mendler MH, Turlin B, Moirand R et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 117, 1155-1163 (1999). (Pubitemid 29512675)
9. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94, 2467-2474 (1999). (Pubitemid 29420675)
10. Kleiner DE, Brunt EM, Van Natta M et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005). (Pubitemid 40770284)
11. Dianzani MU. Uncoupling of oxidative phosphorylation in mitochondria from fatty livers. Biochim. Biophys. Acta 14, 514-532 (1954).
12. Di Luzio NR, Costales F. Inhibition of the ethanol and carbon tetrachloride induced fatty liver by antioxidants. Exp. Mol. Pathol. 4, 141-154 (1965).
13. Adinolf LE, Restivo L. Does vitamin E cure nonalcoholic steatohepatitis? Expert Rev. Gastroenterol. Hepatol. 5(2), 147-150 (2011).
14. Caldwell SH, Swerdlow RH, Khan EM et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J. Hepatol. 31, 430-434 (1999). (Pubitemid 29408724)
15. Jayakumar S, Guillot S, Argo C, Redick J, Caldwell S. Ultrastructural fndings in human nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol. 5(2), 141-145 (2011).
16. Falk Symposium 121 Steatohepatitis (NASH and ASH). Leuschner U, James O, Dancygier H (Eds). Kluwier Academics Publishers, Berlin, Germany (2001).
17. Sanyal AJ; American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123, 1705-1725 (2002). (Pubitemid 35231670)
18. Fatty Liver Disease. NASH and Related Disorders. Farrell GC, George J, De La M Hall P, McCullough AJ (Eds). Blackwell Publishing, NJ, USA (2005).
19. Cortez-Pinto H, de Moura MC, Day CP. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J. Hepatol. 44, 197-208 (2006). (Pubitemid 41772535)
20. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL special conference. J. Hepatol. 53, 372-384 (2010).
21. Loria P, Adinolf LE, Bellentani S et al.; NAFLD Expert Committee of the Associazione Italiana per lo studio del Fegato. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig. Liver Dis. 42, 272-282 (2010).
22. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide defnition. A Consensus Statement from the International Diabetes Federation. Diabet. Med. 23, 469-480 (2006).
23. Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed? Dig. Dis. 23, 72-82 (2005). (Pubitemid 40827665)
24. Brunt EM. What's in a name? Hepatology 50, 663-667 (2009).
25. Loomba R, Wesley R, Pucino F, Liang TJ, Kleiner DE, Lavine JE. Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. Clin. Gastroenterol. Hepatol. 6, 1243-1248 (2008).
26. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity Ann. Med. DOI: 10.3109/07853890.2010.518623 (2010) (Epub ahead of print).
27. Lonardo A, Adinolf LE, Loria P. Mechanisms of hepatitis C virus-induced fatty liver disease. Hot Topics Viral Hepatitis 5, 23-28 (2009).
28. Pattullo V, Douglas MW, George J. Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis? Expert Rev. Gastroenterol. Hepatol. 5(2), 265-277 (2011).
29. Lonardo A, Bellentani S, Ratziu V, Loria P. Insulin resistance in nonalcoholic steatohepatitis: necessary but not suffcient-death of a dogma from analysis of therapeutic studies? Expert Rev. Gastroenterol. Hepatol. 5(2), 279-289 (2011).
30. Arrese M. Burning hepatic fat: therapeutic potential for liver-specifc thyromimetics in the treatment of nonalcoholic fatty liver disease. Hepatology 49, 348-351 (2009).
31. Marchesini G, Ridolf V, Nepoti V. Hepatotoxicity of fast food? Gut 57, 568-570 (2008). (Pubitemid 351579964)
32. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am. J. Med. 108, 9-13 (2000). (Pubitemid 30058272)
33. Caldwell SH, Harris DM, Patrie JT, Hespenheide EE. Is NASH underdiagnosed among African Americans? Am. J. Gastroenterol. 97, 1496-1500 (2002). (Pubitemid 34664799)
34. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387-1395 (2004). (Pubitemid 39657013)
35. Daly AK, Ballestri S, Carulli L, Loria P, Day CP. Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Rev. Gastroenterol. Hepatol. 5(2), 253-263 (2011).
36. Lombardi B, Pani P, Schlunk FF. Choline-defciency fatty liver: impaired release of hepatic triglycerides. J. Lipid Res. 9, 437-446 (1968).
37. Tarugi P, Lonardo A, Ballarini G et al. Fatty liver in heterozygous hypobet alipoproteinemia caused by a novel truncated form of apolipoprotein B. Gastroenterology 111, 1125-1133 (1996). (Pubitemid 26327617)
38. Pereira IVA, Stefano JT, Oliveira CPMS. Microsomal triglyceride transfer protein and nonalcoholic fatty liver disease. Expert Rev. Gastroenterol. Hepatol. 5(2), 245-251 (2011).
39. Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 40, 1461-1465 (2008).
40. Browning JD, Cohen JC, Hobbs HH. Patatin-like phospholipase domain-containing and the pathogenesis and progression of pediatric nonalcoholic fatty liver disease. Hepatology 52, 1189-1192 (2010).
41. Ricchi M, Odoardi MR, Carulli L et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J. Gastroenterol. Hepatol. 24, 830-840 (2009).
42. Bass NM. Lipidomic dissection of nonalcoholic steatohepatitis: moving beyond foie gras to fat traffc. Hepatology 51, 4-7 (2010).
43. Sanyal AJ. Insulin resistance and tissue repair: a 'fato-logical' phenomenon. Gastroenterology 125, 1886-1889 (2003). (Pubitemid 37500454)
44. Hotamisligil GS. Infammation and metabolic disorders. Nature 444, 860-867 (2006).
45. Lonardo A, Lombardini S, Scaglioni F et al. Hepatic steatosis and insulin resistance: does etiology make a difference? J. Hepatol. 44, 190-196 (2006). (Pubitemid 41772534)
46. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fbrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 51, 371-379 (2009).
47. Harmon RC, Tiniakos DG, Argo CK. Infammation in nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol. 5(2), 189-200 (2011).
48. De Minicis S, Svegliati-Baroni G. Fibrogenesis in nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol. 5(2), 179-187 (2011).
49. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study JAMA 282, 1659-1664 (1999). (Pubitemid 29513973)
50. Seifalian AM, Piasecki C, Agarwal A, Davidson BR. The effect of graded steatosis on fow in the hepatic parenchymal microcirculation. Transplantation 68, 780-784 (1999). (Pubitemid 29468195)
51. Farrell GC, Teoh NC, McCuskey RS. Hepatic microcirculation in fatty liver disease. Anat Rec. (Hoboken) 291, 684-692 (2008).
52. Caldwell SH, de Freitas LA, Park SH et al. Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis. Hepatology 49, 1888-1895 (2009).
53. Serviddio G, Bellanti F, Vendemiale G, Altomare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol. 5(2), 233-244 (2011).
54. Machado MV, Cortez-Pinto H. Cell death and nonalcoholic steatohepatitis: where is ballooning relevant? Expert Rev. Gastroenterol. Hepatol. 5(2), 213-222 (2011).
55. Alkhouri N, Carter-Kent C, Feldstein AE. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev. Gastroenterol. Hepatol. 5(2), 201-212 (2011).
56. Amir M, Czaja MJ. Autophagy in nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol. 5(2), 159-166 (2011).
57. Lonardo A, Loria P. NAFLD and cardiovascular risk: direct evidence for the tale of two ages. Am. J. Gastroenterol. 104, 1851-1852 (2009)
58. Lackner C Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist s perspective. Expert Rev. Gastroenterol. Hepatol. 5(2), 223-231 (2011).
59. Caldwell S, Ikura Y, Dias D et al. Hepatocellular ballooning in NASH. J. Hepatol. 53, 719-723 (2010).
60. Molnar A, Haybaeck J, Lackner C, Strnad P. The cytoskeleton in nonalcoholic steatohepatitis-100 years old but still youthful. Expert Rev. Gastroenterol. Hepatol. 5(2), 167-177 (2011).